Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Morgan Stanley Reaffirms Their Hold Rating on Galapagos (GLPG)
Galapagos Analyst Ratings
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Analysts Are Neutral on These Healthcare Stocks: Baxter International (BAX), Galapagos (GLPG)
Galapagos (GLPG) Gets a Hold From Morgan Stanley
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Cuts Target Price to $32
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Oncolytics Biotech (ONCY) and Irhythm Technologies (IRTC)
Kepler Capital Sticks to Its Hold Rating for Galapagos (0JXZ)
Raymond James Initiates Galapagos(GLPG.US) With Hold Rating
TD Cowen Maintains Galapagos(GLPG.US) With Buy Rating
Galapagos (GLPG) Receives a Buy From TD Cowen
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $35
Galapagos (GLPG) Receives a Hold From Morgan Stanley
Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)
Kepler Capital Sticks to Their Hold Rating for Galapagos (GLPG)